[1. [No authors listed] Clofibrate and niacin in coronary heart disease, JAMA 231 (1975) 360-381; DOI: 10.1001/jama.1975.03240160024021.10.1001/jama.1975.03240160024021]Search in Google Scholar
[2. P. L. Canner, K. G. Berge, N. K. Wenger, J. Stamler, L. Friedman, R. J. Prineas and W. Friedewald, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin, J. Am. Coll. Cardiol. 8 (1986) 1245-1255; DOI: 10.1016/S0735-1097(86)80293-5.10.1016/S0735-1097(86)80293-5]Search in Google Scholar
[3. W. Hochholzer, D. D. Berg and R. P. Giugliano, The facts behind niacin, Ther. Adv. Cardiovasc. Dis. 5 (2011) 227-240; DOI: 10.1177/1753944711419197.10.1177/175394471141919721893559]Search in Google Scholar
[4. L. A. Carlson, A. Hamsten and A. Asplund, Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid, J. Intern. Med. 226 (1989) 271-276; DOI: 10.1111/j.1365-2796.1989.tb01393.x.10.1111/j.1365-2796.1989.tb01393.x2530298]Search in Google Scholar
[5. R. S. Birjmohun, B. A. Hutten, J. J. Kastelein and E. S. Stroes, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials, J. Am. Coll. Cardiol. 45 (2005) 185-197; DOI: 10.1016/j.jacc.2004.10.031.10.1016/j.jacc.2004.10.03115653014]Search in Google Scholar
[6. L. A. Carlson, Nicotinic acid and other therapies for raising high-density lipoprotein, Curr. Opin.Cardiol. 21 (2006) 336-344; DOI: 10.1097/01.hco.0000231404.76930.e9.10.1097/01.hco.0000231404.76930.e916755203]Search in Google Scholar
[7. V. S. Kamanna and M. L. Kashyap, Mechanism of action of niacin, Am. J. Cardiol. 101 (2008) 20B-26B; DOI: 10.1016/j.amjcard.2008.02.029.10.1016/j.amjcard.2008.02.02918375237]Search in Google Scholar
[8. L. H. Zhang, V. S. Kamanna, S. H. Ganji, X. M. Xiong and M. L. Kashyap, Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells, J. Lipid Res. 53 (2012) 941-950; DOI: 10.1194/jlr.M020917.10.1194/jlr.M020917332939322389325]Search in Google Scholar
[9. T. Sakai, V. S. Kamanna and M. L. Kashyap, Niacin, but not gemfibrozil, selectively increases LPAI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1783-1789; DOI: 10.1161/hq1001.096624.10.1161/hq1001.09662411701466]Search in Google Scholar
[10. A. Otocka-Kmiecik, D. P. Mikhailidis, S. J. Nicholls, M. Davidson, J. Rysz and M. Banach, Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease, Prog.Lipid Res. 51 (2012) 314-324; DOI: 10.1016/j.plipres.2012.03.003.10.1016/j.plipres.2012.03.00322609245]Search in Google Scholar
[11. C. Mineo and P. W. Shaul, Novel biological functions of high-density lipoprotein cholesterol, Circ. Res. 111 (2012) 1079-1090; DOI: 10.1161/CIRCRESAHA.111.258673.10.1161/CIRCRESAHA.111.258673350060623023510]Search in Google Scholar
[12. L. A. Carlson and G. Rosenhamer, Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid, Acta Med. Scand. 223 (1988) 405-418; DOI: 10.1111/j.0954-6820.1988.tb15891.x.10.1111/j.0954-6820.1988.tb15891.x3287837]Search in Google Scholar
[13. D. H. Blankenhorn, S. A. Nessim, R. L. Johnson, M. E. Sanmarco, S. P. Azen and L. Cashin-Hemphill, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts, JAMA 257 (1987) 3233-3240; DOI: 10.1001/jama.1987.03390230069027.10.1001/jama.1987.03390230069027]Search in Google Scholar
[14. G. Brown, J. J. Albers, L. D. Fisher, S. M. Schaefer, J. T. Lin, C. Kaplan, X. Q. Zhao, B. D. Bisson, V. F. Fitzpatrick and H. T. Dodge, Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B, N. Engl. J. Med. 323 (1990) 1289-1298; DOI: 10.1056/NEJM199011083231901.10.1056/NEJM1990110832319012215615]Search in Google Scholar
[15. W. E. Boden, J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, W. Weintraub and collaborators (316), Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N. Engl. J. Med. 365 (2011) 2255-2267; DOI: 10.1056/ NEJMoa1107579.10.1056/NEJMoa110757922085343]Search in Google Scholar
[16. HPS2-THRIVE collaborative group (1472), M. J. Landray, R. Haynes, J. C. Hopewell, S. Parish, T. Aung, J. Tomson, K. Wallendszus, M. Craig, L. Jiang, R. Collins and J. Armitage, Effects of extended- release niacin with laropiprant in high-risk patients, N. Engl. J. Med. 371 (2014) 203-212; DOI: 10.1056/NEJMoa1300955.10.1056/NEJMoa130095525014686]Search in Google Scholar
[17. J. R. Guyton, M. E. McGovern and L. A. Carlson, Niacin (Nicotinic Acid), in Clinical Lipidology. A Companion to Braunwald´s Heart Disease (Ed. C. M. Ballantyne), 2nd ed., Elsevier, Sainders, Philadelphia 2015, pp. 274-284.]Search in Google Scholar
[18. S. J. Nicholls, Is niacin ineffective? Or did AIM-HIGH miss its target?, Clev. Clin. J. Med. 79 (2012) 38-43; DOI: 10.3949/ccjm.79a.11166.10.3949/ccjm.79a.1116622219232]Search in Google Scholar
[19. Z. Blomgarden and Y. Handelsman, Did AIM-HIGH aim too low?, J. Diabetes 4 (2012) 1-2; DOI: 10.1111/j.1753-0407.2011.00176.x.10.1111/j.1753-0407.2011.00176.x22141573]Search in Google Scholar
[20. J. R. Guyton, A. E. Slee, T. Anderson, J. L. Fleg, R. B. Goldberg, M. L. Kashyap, S. M. Marcovina, S. D. Nash, K. D. O‘Brien, W. S. Weintraub, P. Xu, X. Q. Zhao and W. E. Boden, Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes), J. Am. Coll. Cardiol. 62 (2013) 1580-1584; DOI: 10.1016/j.jacc.2013.07.023.10.1016/j.jacc.2013.07.023386244623916935]Search in Google Scholar
[21. I. Gaidarov, X. Chen, T. Anthony, D. Maciejewski-Lenoir, C. Liaw and D. J. Unett, Differential tissue and ligand-dependent signaling of GPR109A receptor: Implications for anti-atherosclerotic therapeutic potential, Cell. Signal. 25 (2013) 2003-2016; DOI: 10.1016/j.cellsig.2013.06.008.10.1016/j.cellsig.2013.06.00823770183]Search in Google Scholar
[22. Y. L. Yang, M. Hu, M. Chang and B. Tomlinson, A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients, J. Clin. Pharm. Ther. 38 (2013) 528-532; DOI: 10.1111/jcpt.12096.10.1111/jcpt.1209624020480]Search in Google Scholar
[23. M. Zeman, M. Vecka, F. Perlík, R. Hromádka, B. Stanková, E. Tvrzická and A. Žák, Niacin in the treatment of hyperlipidemias in light of new clinical trials: Has niacin lost its place?, Med. Sci. Monit. 21 (2015) 2156-2162; DOI: 10.12659/MSM.893619.10.12659/MSM.893619452300626210594]Search in Google Scholar
[24. J. T. Chai, J. E. Digby and R. P. Choudhury, GPR109A and vascular inflammation, Curr. Atheroscler. Rep. 15 (2013) 325 (10 pages); DOI: 10.1007/s11883-013-0325-9.10.1007/s11883-013-0325-9363111723526298]Search in Google Scholar
[25. M. Lukasova, J. Hanson, S. Tunaru and S. Offermanns, Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potential, Trends Pharmacol. Sci. 32 (2011) 700-707; DOI: 10.1016/j.tips.2011.08.002.10.1016/j.tips.2011.08.00221944259]Search in Google Scholar
[26. L-H. Zhang, V. S. Kamanna, M. C. Zhang and M. L. Kashyap, Niacin inhibits surface expression of ATP synthase b chain in HepG2 cells: implications for raising HDL, J. Lipid Res. 49 (2008) 1195-1201; DOI: 10.1194/jlr.M700426-JLR200.10.1194/jlr.M700426-JLR20018316796]Search in Google Scholar
[27. S. H. Ganji, S. Tavintharan, D. Zhu, Y. Xing, V. S. Kamanna and M. L. Kashyap, Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells, J. Lipid Res. 45 (2004) 1835-1845; DOI: 10.1194/jlr.M300403-JLR200.10.1194/jlr.M300403-JLR20015258194]Search in Google Scholar
[28. B. J. Wu, L. Yan, F. Charlton, P. Witting, P. J. Barter and K. A. Rye, Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 968-975; DOI: 10.1161/ATVBAHA.109.201129.10.1161/ATVBAHA.109.20112920167660]Search in Google Scholar
[29. J. E. Digby, E. McNeill, O. J. Dyar, V. Lam, D. R. Greaves and R. P. Choudhury, Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, rantes, and mcp-1 and upregulation of adiponectin, Atherosclerosis 209 (2010) 89-95; DOI: 10.1016/j.atherosclerosis.2009.08.045.10.1016/j.atherosclerosis.2009.08.045283907519781706]Search in Google Scholar
[30. J. E. Digby, F. Martinez, A. Jefferson, N. Ruparelia, J. Chai, M. Wamil, D. R. Graves and R. P. Choudhury, Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms, Arterioscl. Thromb. Vas. Biol. 32 (2012) 669-676; DOI: 10.1161/ ATVBAHA.111.241836.10.1161/ATVBAHA.111.241836339259822267479]Search in Google Scholar
[31. D. H. Endemann and E. L. Schiffrin, Endothelial dysfunction, J. Am. Soc. Nephrol. 15 (2004) 1983-1992; DOI: 10.1097/01.ASN.0000132474.50966.DA.10.1097/01.ASN.0000132474.50966.DA15284284]Search in Google Scholar
[32. H. N. Siti, Y. Kamisah and J. Kamsiah, The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review), Vascul. Pharmacol. 71 (2015) 40-56; DOI: 10.1016/j. vph.2015.03.005. ]Search in Google Scholar
[33. B. Chen, Y. Lu, Y. Chen and J. Cheng, The role of Nrf2 in oxidative stress-induced endothelial injuries, J. Endocrinol. 225 (2015) R83-R99; DOI: 10.1530/JOE-14-0662.10.1530/JOE-14-066225918130]Search in Google Scholar
[34. S. H. Ganji, S. Qin, L. Zhang, V. S. Kamanna and M. L. Kashyap, Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells, Atherosclerosis 202 (2009) 68-75; DOI: 10.1016/j.atherosclerosis.2008.04.044.10.1016/j.atherosclerosis.2008.04.04418550065]Search in Google Scholar
[35. S. Tavintharan, S. C. Lim and C. F. Sum, Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells, Basic Clin. Pharmacol. Toxicol. 104 (2009) 206-210; DOI: 10.1111/j.1742-7843.2008.00364.x.10.1111/j.1742-7843.2008.00364.x19159436]Search in Google Scholar
[36. E. P. Plaisance, M. Lukasova, S. Offermanns, Y. Zhang, G. Cao and R. L. Judd, Niacin stimulates adiponectin secretion through the GPR109A receptor, Am. J. Physiol. Endocrinol. Metab. 296 (2009) E549-E558; DOI: 10.1152/ajpendo.91004.2008.10.1152/ajpendo.91004.200819141678]Search in Google Scholar
[37. M. Iantorno, U. Campia, N. Di Daniele, S. Nistico, G. B. Forleo, C. Cardillo and M. Tesauro, Obesity, inflammation and endothelial dysfunction, J. Biol. Regul. Homeost. Agents 28 (2014) 169-176.]Search in Google Scholar
[38. A. Warnholtz, P. Wild, M. A. Ostad, V. Elsner, F. Stieber, R. Schinzel, U. Walter, D. Peetz, K. Lackner, S. Blankenberg and T. Munzel, Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study, Atherosclerosis 204 (2009) 216-221; DOI: 10.1016/j.atherosclerosis.2008.08.003.10.1016/j.atherosclerosis.2008.08.00318822413]Search in Google Scholar
[39. S. Sahebkar, Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials, Vasc. Med. 19 (2014) 54-66; DOI: 10.1177/1358863X13515766.10.1177/1358863X1351576624391126]Search in Google Scholar
[40. S. Westphal, K. Borucki, C. Luley, J. Martens-Lobenhoffer and S. M. Bode-Böger, Treatment with niacin lowers ADMA, Atherosclerosis 184 (2006) 448-450; DOI: 10.1016/j.atherosclerosis.2005.11.018.10.1016/j.atherosclerosis.2005.11.01816376893]Search in Google Scholar
[41. B. J. Wu, K. Chen, P. J. Barter and K. A. Rye, Niacin inhibits vascular inflammation via the induction of heme oxygenase-1, Circulation 125 (2012) 150-158; DOI: 10.1161/CIRCULATIONAHA.111.053108.10.1161/CIRCULATIONAHA.111.05310822095827]Search in Google Scholar
[42. K. H. Cho, H. J. Kim, B. Rodriguez-Iturbe and N. D. Vaziri, Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure, Am. J. Physiol. Renal Physiol. 297 (2009) F106-F113; DOI: 10.1152/ajprenal.00126.2009.10.1152/ajprenal.00126.200919420110]Search in Google Scholar
[43. A. El Atrash, L. Dawood, E. Tousson and A. Salama, Neuroprotective role of vitamin B3 in experimentally induced oxidative stress, Int. J. Clin. Exp. Neurol. 3 (2015) 21-25; DOI: 10.12691/ijcen-3-1-4.]Search in Google Scholar
[44. S. Hamoud, M. Kaplan, E. Meilin, A. Hassan, R. Torgovicky, R. Cohen and T. Hayek, Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol, Am. J. Med. Sci. 345 (2013) 195-199; DOI: 10.1097/ MAJ.0b013e3182548c28.10.1097/MAJ.0b013e3182548c2822990043]Search in Google Scholar
[45. A. Kei, C. Tellis, E. Liberopoulos, A. Tselepis and M. Elisaf, Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia, Cardiovasc. Ther. 32 (2014) 139-146; DOI: 10.1111/1755-5922.12072.10.1111/1755-5922.1207224618208]Search in Google Scholar
[46. M Lukasova, C. Malaval, A. Gille, J. Kero and S. Offermanns, Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells, J. Clin. Invest. 121 (2011) 1163-1173; DOI: 10.1172/JCI41651.10.1172/JCI41651304885421317532]Search in Google Scholar
[47. W. Y. Kwon, G. J. Suh, K. S. Kim and Y. H. Kwak, Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-kB pathway, Crit. Care Med. 39 (2011) 328-334; DOI: 10.1097/CCM.0b013e3181feeae4.10.1097/CCM.0b013e3181feeae420975550]Search in Google Scholar
[48. Y. Si, Y. Zhang, J. Zhao, S. Guo, L. Zhai, S. Yao, H. Sang, N. Yang, G. Song, J. Gu and S. Qin, Niacin inhibits vascular inflammation via downregulating nuclear transcription factor-kB signaling pathway, Mediators Inflamm. 2014 (2014) article ID 263786 (12 pages); DOI: 10.1155/2014/263786.10.1155/2014/263786405849524991087]Search in Google Scholar
[49. J. T. Kuvin, D. M. Dave, K. A. Sliney, P. Mooney, A. R. Patel, C. D. Kimmelstiel and R. H. Karas, Effects of extended release niacin on lipoprotein particle size, distribution, an inflammatory markers in patients with coronary artery disease, Am. J. Cardiol. 98 (2006) 743-745; DOI:10.1016/j. amjcard.2006.04.011.]Search in Google Scholar
[50. M. Thoenes, A. Oguchi, S. Nagamia, C. S. Vaccari, R. Hammoud, G. E. Umpierrez and B. V. Khan, The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome, Int. J. Clin. Pract. 61 (2007) 1942-1948; DOI: 10.1111/j.1742-1241.2007.01597.x.10.1111/j.1742-1241.2007.01597.x17935553]Search in Google Scholar
[51. P. M. Ridker, M. J. Stampfer and N. Rifai, Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease, JAMA 285 (2001) 2481-2485; DOI: 10.1001/ jama.285.19.2481.10.1001/jama.285.19.248111368701]Search in Google Scholar
[52. N. Singh, A. Gurav, S. Sivaprakasam, E. Brady, R. Padia, H. Shi, M. Thangaraju, P. D. Prasad, S. Manicassamy, D. H. Munn, J. R. Lee, S. Offermanns and V. Ganapathy, Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis, Immunity 40 (2014) 128-139; DOI: 10.1016/j.immuni.2013.12.007.10.1016/j.immuni.2013.12.007430527424412617]Search in Google Scholar
[53. J. O. Johansson, N. Egberg, A. Asplund-Carlson and L. A. Carlson, Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men, J. Cardiovasc. Risk 4 (1997) 165-171; DOI: 10.1177/174182679700400302.10.1177/174182679700400302]Search in Google Scholar
[54. S. Tavintharan, M. Sivakumar, S. C. Lim and C. F. Sum, Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells, Clin. Chim. Acta 376 (2007) 41-44; DOI: 10.1016/j. cca.2006.07.009.]Search in Google Scholar
[55. R. S. Rosenson, Antiatherothrombotic effects of nicotinic acid, Atherosclerosis 171 (2003) 87-96; DOI: 10.1016/j.atherosclerosis.2003.07.003.10.1016/j.atherosclerosis.2003.07.00314642410]Search in Google Scholar
[56. G. Lowe, A. Rumley, J. Norrie, I. Ford, J. Shepherd, S. Cobbe, P. Macfarlane and C. Packard, Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study, Thromb. Haemost. 84 (2000) 553-558. Erratum in: Thromb. Haemost. 85 (2001) 946.]Search in Google Scholar
[57. L. Wilhelmsen, K. Svärdsudd, K. Korsan-Bengtsen, B. Larsson, L. Welin and G. Tibblin, Fibrinogen as a risk factor for stroke and myocardial infarction, N. Engl. J. Med. 311 (1984) 501-505; DOI: 10.1056/NEJM198408233110804.10.1056/NEJM1984082331108046749207]Search in Google Scholar
[58. W. B. Kannel, P. A. Wolf, W. P. Castelli and R. B. D‘Agostino, Fibrinogen and risk of cardiovascular disease. The Framingham Study, JAMA 258 (1987) 1183-1186; DOI:10.1001/jama.1987.03400090067035.10.1001/jama.1987.03400090067035]Search in Google Scholar
[59. J. Ma, C. H. Hennekens, P. M. Ridker and M. J. Stampfer, A prospective study of fibrinogen and risk of myocardial infarction in the physicians‘ health study, J. Am. Coll. Cardiol. 33 (1999) 1347-1352; DOI:10.1016/S0735-1097(99)00007-8.10.1016/S0735-1097(99)00007-8]Search in Google Scholar
[60. P. Y. Scarabin, D. Arveiler, P. Amouyel, C. Dos Santos, A. Evans, G. Luc, J. Ferrières and I. Juhan- Vague, Prospective epidemiological study of myocardial infarction. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study, Atherosclerosis 166 (2003) 103-109; DOI: 10.1016/S0021-9150(02)00309-X.10.1016/S0021-9150(02)00309-X]Search in Google Scholar
[61. A. Kei and M. Elisaf, Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patiens with primary dyslipidemia, Arch. Med. Sci. 3 (2014) 439-444; DOI: 10.5114/ aoms.2014.43738.10.5114/aoms.2014.43738410725025097572]Search in Google Scholar
[62. K. Stach, F. Zaddach, X. D. Nguyen, E. Elmas, S. Kralev, C. Weiß, M. Borggrefe and T. Kälsch, Effects of nicotinic acid on endothelial cells and platelets, Cardiovasc. Pathol. 21 (2012) 89-95; DOI: 10.1016/j.carpath.2011.04.002.10.1016/j.carpath.2011.04.00221632263]Search in Google Scholar
[63. A. M. Gotto and H. Pownall, Manual of Lipid Disorders, 3rd ed., Lippincott Williams & Wilkins, Philadelphia 2003.]Search in Google Scholar
[64. L. A. Carlson, Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review, J. Intern. Med. 258 (2005) 94-114; DOI: 10.1111/j.1365-2796.2005.01528.x.10.1111/j.1365-2796.2005.01528.x16018787]Search in Google Scholar
[65. [The Emerging Risk Factors Collaboration] S. Erqou, S. Kaptoge, P. L. Perry, E. A. Di Angelantonio, I. R. Thompson, S. M. White, R. Marcovina, R. Collins, S. G. Thompson and J. Danesh, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality, JAMA 302 (2009) 412-423; DOI: 10.1001/jama.2009.1063.10.1001/jama.2009.1063327239019622820]Search in Google Scholar
[66. M. L. Koschinsky and S. M. Marcovina, Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity, Curr. Opin. Lipidol. 15 (2004) 167-167; DOI: 10.1097/01.mol.0000124528.75650.be.]Search in Google Scholar
[67. S. Tsimikas, L. D. Tsironis and A. D. Tselepis, New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2094-2099; DOI: 10.1161/01.ATV.0000280571.28102.d4..]Search in Google Scholar
[68. S. Tsimikas, J. Willeit, M. Knoflach, M. Mayr, G. Egger, M. Notdurfter, J. L. Witztum, C. J. Wiedermann, Q. Xu and S. Kiechl, Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study, Eur. Heart J. 30 (2009) 107-115; DOI: 10.1093/eurheartj/ehn502.10.1093/eurheartj/ehn50219019993]Search in Google Scholar
[69. V. Serebruany, A. Malinin, D. Aradi, W. Kuliczkowski, N. B. Norgard and W. E. Boden, The in vitro effects of niacin on platelet biomarkers in human volunteers, Thromb. Haemost. 104 (2010) 311-317; DOI: 10.1160/TH10-01-0015.10.1160/TH10-01-001520539903]Search in Google Scholar
[70. M. Liu and F. Liu, Transcriptional and post-translational regulation of adiponectin, Biochem. J. 425 (2009) 41-52; DOI: 10.1042/BJ20091045.10.1042/BJ2009104520001961]Search in Google Scholar
[71. H. Kobayashi, N. Ouchi, S. Kihara, K. Walsh, M. Kumada, Y. Abe, T. Funahashi and Y. Matsuzawa, Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin, Circ. Res. 94 (2004) e27-e31; DOI: 10.1161/01.RES.0000119921.86460.37.10.1161/01.RES.0000119921.86460.37437447914752031]Search in Google Scholar
[72. M. Kumada, S. Kihara, S. Sumitsuji, T. Kawamoto, S. Matsumoto, N. Ouchi, Y. Arita, Y. Okamoto, I. Shimomura, H. Hiraoka, T. Nakamura, T. Funahashi, Y. Matsuzawa and Osaka CAD Study Group. Coronary artery disease, Association of hypoadiponectinemia with coronary artery disease in men, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 85-89; DOI: 10.1161/01.ATV.0000048856.22331.50.10.1161/01.ATV.0000048856.22331.50]Search in Google Scholar
[73. F. Otsuka, S. Sugiyama, S. Kojima, H. Maruyoshi, T. Funahashi, K. Matsui, T. Sakamoto, M. Yoshimura, K. Kimura, S. Umemura and H. Ogawa, Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease, J. Am. Coll. Cardiol. 48 (2006) 1155-1162; DOI: 10.1016/j.jacc.2006.05.054.10.1016/j.jacc.2006.05.05416978998]Search in Google Scholar
[74. T. Pischon, C. J. Girman, G. S. Hotamisligil, N. Rifai, F. B. Hu and E. B. Rimm, Plasma adiponectin levels and risk of myocardial infarction in men, JAMA 291 (2004) 1730-1737; DOI: 10.1001/ jama.291.14.1730.10.1001/jama.291.14.173015082700]Search in Google Scholar
[75. W. Koenig, N. Khuseinova, J. Baumert, C. Meisinger and H. Löwel, Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany, J. Am. Coll. Cardiol. 48 (2006) 1369-1377; DOI: 10.1016/j.jacc.2006.06.053.10.1016/j.jacc.2006.06.05317010797]Search in Google Scholar
[76. C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg and P. Hildebrandt, Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure, Circulation 112 (2005) 1756-1762; DOI: 10.1161/CIRCULATIONAHA.104.530972.10.1161/CIRCULATIONAHA.104.53097216157772]Search in Google Scholar
[77. T. Nakamura, H. Funayama, N. Kubo, T. Yasu, M. Kawakami, M. Saito, S. Momomura and S. E. Ishikawa, Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure, Circ. J. 70 (2006) 1557-1562; DOI: 10.1253/circj.70.1557.10.1253/circj.70.155717127799]Search in Google Scholar
[78. T. Tamura, Y. Furukawa, R. Taniguchi, Y. Sato, K. Ono, H. Horiuchi, Y. Nakagawa, T. Kita and T. Kimura, Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure, Circ. J. 71 (2007) 623-630; DOI: 10.1253/circj.71.623.10.1253/circj.71.62317456982]Search in Google Scholar
[79. L. Chen, W. Y. So, S. Y. Li, Q. Cheng, B. J. Boucher and P. S. Leung, Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets, Mol. Cell. Endocrinol. 404 (2015) 56-66; DOI: 10.1016/j.mce.2015.01.029. 10.1016/j.mce.2015.01.02925622782]Search in Google Scholar
[80. T. E. Graham, Q. Yang, M. Blüher, A. Hammarstedt, T. P. Ciaraldi, R. R. Henry, C. J. Wason, A. Oberbach, P. A. Jansson, U. Smith and B. B. Kahn, Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects, N. Engl. J. Med. 354 (2006) 2552-2563; DOI: 10.1056/NEJMoa054862.10.1056/NEJMoa05486216775236]Search in Google Scholar
[81. Q. Yang, T. E. Graham, N. Mody, F. Preitner, O. D. Peroni, J. M. Zabolotny, K. Kotani, L. Quadro and B. B. Kahn, Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes, Nature 436 (2005) 356-362; DOI: 10.1038/nature03711.10.1038/nature0371116034410]Search in Google Scholar
[82. V. C. Luft, M. Pereira, J. S. Pankow, C. Ballantyne, D. Couper, G. Heiss and B. B. Duncan, Retinol binding protein 4 and incident diabetes - the Atherosclerosis Risk in Communities Study (ARIC Study), Rev. Bras. Epidemiol. 16 (2013) 388-397; DOI: 10.1590/S1415-790X2013000200014.10.1590/S1415-790X2013000200014492999624142010]Search in Google Scholar
[83. B. Vergès, B. Guiu, J. P. Cercueil, L. Duvillard, I. Robin, P. Buffier, B. Bouillet, S. Aho, M. C. Brindisi and J. M. Petit, Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus, Arterioscler. Thromb. Vasc. Biol. 32 (2012) 3050-3057; DOI: 10.1161/ATVBAHA.112.255190.10.1161/ATVBAHA.112.25519023087360]Search in Google Scholar
[84. D. Wanders, Novel Pleiotropic Effects of Niacin, Ph. D. Thesis, Auburn University, Auburn (AL, USA) 2012.]Search in Google Scholar
[85. M. M. Heemskerk, H. K. Dharuri, S. A. van den Berg, H. S. Jónasdóttir, D. P. Kloos, M. Giera, K. W. van Dijk and V. van Harmelen, Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile, J. Lipid Res. 55 (2014) 2532-2540; DOI: 10.1194/jlr.M051938.10.1194/jlr.M051938424244625320342]Search in Google Scholar
[86. R. Fischer, A. Konkel, H. Mehling, K. Blossey, A. Gapelyuk, N. Wessel, C. von Schacky, R. Dechend, D. N. Muller, M. Rothe, F. C. Luft, K. Weylandt and W. H. Schunck, Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway, J. Lipid Res. 55 (2014) 1150-1164; DOI: 10.1194/jlr.M047357.10.1194/jlr.M047357403194624634501]Search in Google Scholar
[87. S. H. Ganji, G. D. Kukes, N. Lambrecht, M. L. Kashyap and V. S. Kamanna, Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease, Am. J. Physiol. Gastrointest. Liver Physiol. 306 (2014) G320-G327; DOI: 10.1152/ajpgi.00181.2013.10.1152/ajpgi.00181.201324356885]Search in Google Scholar
[88. M. Hara, M. Kurano, K. Tsuneyama, K. Kikuchi, A. Takai, T. Matsushima and K. Tsukamoto, Nicotinic acid prevents and restores steatohepatitis together with amelioration of postprandial dyslipidemia, Arterioscler. Thromb. Vasc. Biol. 34 (2014) A601. American Heart Association (AHA) Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Spring Conference, Toronto, Canada, May 1-3, 2014.]Search in Google Scholar
[89. T. H. Grahn, R. Kaur, J. Yin, M. Schweiger, V. M. Sharma, M. J. Lee, Y. Ido, C. M. Smas, R. Zechner, A. Lass and V. Puri, Fat-specific protein 27 (FSP27) interacts with adipose triglyceride lipase (ATGL) to regulate lipolysis and insulin sensitivity in human adipocytes, J. Biol. Chem. 289 (2014) 12029-12039; DOI: 10.1074/jbc.M113.539890.10.1074/jbc.M113.539890400210924627478]Search in Google Scholar
[90. E. Fabbrini, B. S. Mohammed, K. M. Korenblat, F. Magkos, J. McCrea, B. W. Patterson and S. Klein, Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease, J. Clin. Endocrinol. Metab. 95 (2010) 2727-2735; DOI: 10.1210/jc.2009-2622.10.1210/jc.2009-2622290207620371660]Search in Google Scholar
[91. M. Hu, W. C. Chu, S. Yamashita, D. K. Yeung, L. Shi, D. Wang, D. Masuda, Y. Yang and B. Tomlinson, Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients, J. Lipid Res. 53 (2012) 802-809; DOI: 10.1194/jlr.P023614.10.1194/jlr.P023614330765722315393]Search in Google Scholar
[92. R. N. Foley, P. S. Parfrey and M. J. Sarnak, Epidemiology of cardiovascular disease in chronic renal disease, J. Am. Soc. Nephrol. 9 (Suppl. 12) (1998) S16-S23.]Search in Google Scholar
[93. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch and C. Y. Hsu, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med. 351 (2004) 1296-1305; DOI: 10.1056/NEJMoa041031. 10.1056/NEJMoa04103115385656]Search in Google Scholar
[94. M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, P. Parfrey, M. Pfeffer, L. Raij, D. J. Spinosa and P. W. Wilson, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, Circulation 108 (2003) 2154–2169; DOI: 10.1161/01.CIR.0000095676.90936.80.10.1161/01.CIR.0000095676.90936.8014581387]Search in Google Scholar
[95. J. Omran, A. Al-Dadah and K. C. Dellsperger, Dyslipidemia in patients with chronic and endstage kidney disease, Cardiorenal Med. 3 (2013) 165–177; DOI: 10.1159/000351985. 10.1159/000351985388419024454313]Search in Google Scholar
[96. N. D. Vaziri, Causes of dysregulation of lipid metabolism in chronic renal failure, Semin. Dial. 22 (2009) 644–651; DOI: 10.1111/j.1525-139X.2009.00661.x.10.1111/j.1525-139X.2009.00661.x287432320017835]Search in Google Scholar
[97. V. Tsimihodimos, Z. Mitrogianni and M. Elisaf, Dyslipidemia associated with chronic kidney disease, Open Cardiovasc. Med. J. 5 (2011) 41–48.10.2174/1874192401105010041310635721643500]Search in Google Scholar
[98. E. A. Friedman, Consequences and management of hyperphosphatemia in patients with renal insufficiency, Kidney Int. Suppl. 95 (2005) S1-S7; DOI: 10.1111/j.1523-1755.2005.09500.x.10.1111/j.1523-1755.2005.09500.x15882307]Search in Google Scholar
[99. M. Tonelli, N. Pannu and B. Manns, Oral phosphate binders in patients with kidney failure, N. Engl. J. Med. 362 (2010) 1312–1324; DOI: 10.1056/NEJMra0912522.10.1056/NEJMra091252220375408]Search in Google Scholar
[100. H. J. Kang, D. Y. Kim, S. M. Lee, K. H. Kim, S. H. Han, H. K. Nam, K. H. Kim, S. E. Kim, Y. K. Son and W. S. An, Effect of low-dose niacin on dyslipidemia, serum phosphorus levels and adverse effects in patients with chronic kidney disease, Kidney Res. Clin. Pract. 32 (2013) 21–26; DOI: 10.1016/j.krcp.2012.12.001.10.1016/j.krcp.2012.12.001471610826889433]Search in Google Scholar
[101. D. Maccubbin, D. Tipping, O. Kuznetsova, W. A. Hanlon and A. G. Bostom, Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial, Clin. J. Am. Soc. Nephrol. 5 (2010) 582–589; DOI: 10.2215/CJN.07341009.10.2215/CJN.07341009284970020299362]Search in Google Scholar
[102. P. Aramwit, R. Srisawadwong and O. Supasyndh, Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients, J. Nephrol. 25 (2012) 354–362; DOI: 10.5301/jn.5000011.10.5301/jn.500001121748722]Search in Google Scholar
[103. K. Kitai, H. Tanaka, S. Tatsymi, Y. Fukunaga, K. Genjida, K. Morita, N. Kuboyama, T. Suzuki, T. Akita, K. Miyamoto and E. Takeda, Nicontinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine, Nephrol. Dial. Transplant. 14 (1999) 1195–1201; DOI: 10.1093/ndt/14.5.1195.10.1093/ndt/14.5.119510344361]Search in Google Scholar
[104. S. Shin and S. Lee, Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients, Ther. Clin. Risk Manag. 10 (2014) 875–883; DOI: 10.2147/TCRM.S71559.10.2147/TCRM.S71559]Search in Google Scholar
[105. M. H. Ahmed, Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials, Renal Failure. 32 (2010) 642–646; DOI: 10.3109/08860221003753323.10.3109/08860221003753323]Search in Google Scholar
[106. E. Streja, C. P. Kovesdy, D. A. Streja, H. Moradi, K. Kalantar-Zadeh and M. L. Kashyap, Niacin and progression of CKD, Am. J. Kidney Dis. 65 (2015) 785–798; DOI: 10.1053/j.ajkd.2014.11.033.10.1053/j.ajkd.2014.11.033]Search in Google Scholar
[107. M. Al-Hijji, S. S. Martin, P. H. Joshi and S. R. Jones, Effect of equivalent on-treatment apolipoprotein levels on outcomes (from the AIM-HIGH and HPS2-THRIVE), Am. J. Cardiol. 112 (2013) 1697–1700; DOI: 10.1016/j.amjcard.2013.07.030.10.1016/j.amjcard.2013.07.030]Search in Google Scholar
[108. A. Owada, S. Suda and T. Hata, Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial, Am. J. Med. 114 (2003) 347–353; DOI: 10.1016/S0002-9343(02)01567-X.10.1016/S0002-9343(02)01567-X]Search in Google Scholar
[109. H. Goel and R. L. Dunbar, Niacin alternatives for dyslipidemia: Fool’s gold or gold mine? Part II: Novel niacin mimetics, Curr. Atheroscler. Rep. 18 (2016) article 17 (13 pages); DOI: 10.1007/s11883-016-0570-9.10.1007/s11883-016-0570-9477347426932224]Search in Google Scholar
[110. R. S. Birjmohun, B. A. Hutten, J. J. P. Kastelein and E. S. G. Stroes, Efficacy and safety of highdensity lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials, J. Am. Coll. Cardiol. 45 (2005) 185–197; DOI: 10.1016/j.jacc.2004.10.031.10.1016/j.jacc.2004.10.03115653014]Search in Google Scholar
[111. J. Hanson, A. Gille, S. Zwykiel, M. Lukasova, B. E. Clausen, K. Ahmed, S. Tunaru, A. Wirth and S. Offermanns, Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice, J. Clin. Invest. 120 (2010) 2910-2919; DOI: 10.1172/JCI42273.10.1172/JCI42273291219420664170]Search in Google Scholar
[112. R. H. Stern, J. D. Spence, D. J. Freeman and A. Parbtani, Tolerance to nicotinic acid flushing, Clin. Pharmacol. Ther. 50 (1991) 66-70; DOI: 10.1038/clpt.1991.104.10.1038/clpt.1991.1041855354]Search in Google Scholar
[113. S. Andersson, L. A. Carlson, L. Orö and E. A. Richards, Effect of nicotinic acid on gastric secretion of acid in human subjects and in dogs, Scand. J. Gastroenterol. 6 (1971) 555-559; DOI: 10.3109/00365527109179938.10.3109/003655271091799385139111]Search in Google Scholar
[114. J. McKenney, New perspectives on the use of niacin in the treatment of lipid disorders, Arch. Intern. Med. 164 (2004) 697-705; DOI: 10.1001/archinte.164.7.697.10.1001/archinte.164.7.697]Search in Google Scholar
[115. S. S. Bhardwaj and N. Chalasani, Lipid-lowering agents that cause drug-induced hepatotoxicity, Clin. Liver Dis. 11 (2007) 597-613; DOI: 10.1016/j.cld.2007.06.010.10.1016/j.cld.2007.06.010]Search in Google Scholar
[116. J. R. Guyton and H. E. Bays, Safety considerations with niacin therapy, Am. J. Cardiol. 99 (6, Suppl. 1) (2007) S22-S31; DOI: 10.1016/j.amjcard.2006.11.018.10.1016/j.amjcard.2006.11.018]Search in Google Scholar
[117. J. R. Guyton, S. Fazio, A. J. Adewale, E. Jensen, J. E. Tomassini, A. Shah and A. M. Tershakovec, Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial, Diabetes Care 35 (2012) 857-860; DOI: 10.2337/dc11-1369.10.2337/dc11-1369]Search in Google Scholar
[118. A. M. Poynten, S. K. Gan, A. D. Kriketos, A. O’Sullivan, J. J. Kelly, B. A. Ellis, D. J. Chisholm and L. V. Campbell, Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content, Metabolism 52 (2003) 699-704; DOI: 10.1016/ S0026-0495(03)00030-1.10.1016/S0026-0495(03)00030-1]Search in Google Scholar
[119. L. A. Carlson and L.Oro, The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis, Acta Med. Scand. 172 (1962) 641-645; DOI: 10.1111/j.0954-6820.1962.tb07203.x.10.1111/j.0954-6820.1962.tb07203.x14018702]Search in Google Scholar
[120. M. M. Heemskerk, S. A. A. van den Berg, A. C. M. Pronk, J.-B. van Klinken, M. R. Boon, L. M. Havekes, P. C. N. Rensen, K. W. van Dijk and V. van Harmelen, Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B, Am. J. Physiol. Endocrinol. Metabol. 306 (2014) E808-E813; DOI:10.1152/ ajpendo.00641.2013.]Search in Google Scholar
[121. L. Chen, W. Y. So, S. Y. T. Li, Q. Cheng, B. J. Boucher and P. S. Leung, Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets, Mol. Cell. Endocrinol. 404 (2015) 56-66; DOI: 10.1016/j.mce.2015.01.029.10.1016/j.mce.2015.01.02925622782]Search in Google Scholar
[122. T. P. Wong, L. K. Y. Chan and P. S. Leung, Involvement of the niacin receptor GPR109a in the local control of glucose uptake in small intestine of type 2 diabetic mice, Nutrients 7 (2015) 7543-7561; DOI: 10.3390/nu7095352.10.3390/nu7095352458654726371038]Search in Google Scholar
[123. C. Goldie, A. J. Taylor, P. Nguyen, C. McCoy, X.-Q. Zhao and D. Preiss, Niacin therapy and the risk of new-onset diabetes: A meta-analysis of randomised controlled trials, Heart 102 (2016) 198-203; DOI: 10.1136/heartjnl-2015-308055.10.1136/heartjnl-2015-308055475261326370223]Search in Google Scholar
[124. P. L. Canner, C. D. Furberg, M. L. Terrin and M. E. McGovern, Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project), Am. J. Cardiol. 95 (2005) 254-257; DOI: 10.1016/j.amjcard.2004.09.013.10.1016/j.amjcard.2004.09.01315642562]Search in Google Scholar
[125. S. L.Gershon and I. H. Fox, Pharmacologic effects of nicotinic acid on human purine metabolism, J. Lab. Clin. Med. 84 (1974) 179-186.]Search in Google Scholar
[126. Z. N. Gaut, R. Pocelinko, H. M. Solomon and G. B. Thomas, Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid, Metabolism 20 (1971) 1031-1035; DOI: 10.1016/0026-0495(71)90026-6. 10.1016/0026-0495(71)90026-6]Search in Google Scholar
[127. D. Domanico, F. Verboschi, S. Altimari, L. Zompatori and E. M. Vingolo, Ocular effects of niacin: A review of the literature, Med. Hypothesis Discov. Innov. Ophthalmol. 4 (2015) 64–71.]Search in Google Scholar
[128. H. Stals, C. Vercammen, C. Peeters and M. A. Morren, Acanthosis nigricans caused by nicotinic acid: case report and review of the literature, Dermatology 189 (1994) 203–206; DOI: 10.1159/000246834.10.1159/000246834]Search in Google Scholar
[129. A. G. Gharavi, J. A. Diamond, D. A. Smith and R. A. Phillips, Niacin-induced myopathy, Am. J. Cardiol. 74 (1994) 841–842; DOI: 10.1016/0002-9149(94)90453-7.10.1016/0002-9149(94)90453-7]Search in Google Scholar
[130. A. Pandian, A. Arora, L. S. Sperlinga and B. V. Khan, Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin, Vasc. Health Risk Manag. 4 (2008) 1001–1009; DOI: 10.2147/VHRM.S3460.10.2147/VHRM.S3460260534219183748]Search in Google Scholar